このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

BTK Inhibitor-Containing Bridging Therapy and CAR-T Outcomes in R/R LBCL

Association of Disease Control After BTK Inhibitor-Containing Bridging Therapy and Systemic Inflammatory Phenotypes With CAR T-Cell Outcomes in Relapsed/Refractory Large B-Cell Lymphoma

This observational study will examine outcomes of CAR-T cell therapy in adults with large B-cell lymphoma that has returned or has not responded to prior treatment. Participants will already have received bridging therapy that includes a BTK inhibitor before CAR-T cell infusion.

Researchers will compare outcomes between participants whose lymphoma responded to bridging therapy before CAR-T cell infusion and those whose lymphoma did not respond. The study will use medical records, imaging results, laboratory tests, treatment information, and follow-up data collected during usual care. It will not assign treatment, change medical care, or require extra tests or blood samples.

The study will assess lymphoma response after CAR-T cell therapy, safety, survival, and changes in routine blood markers of inflammation after CAR-T cell therapy.

調査の概要

研究の種類

観察的

入学 (推定)

66

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

確率サンプル

調査対象母集団

The study population comprises adults with relapsed or refractory large B-cell lymphoma (LBCL) who receive routine CAR-T cell therapy at a single center in China. Eligible patients receive BTK inhibitor-containing bridging therapy after leukapheresis and before lymphodepleting chemotherapy and have evaluable disease status after bridging therapy and before CAR-T cell infusion. Patients treated before ethics approval will be identified retrospectively from the center's CAR-T treatment records and routine medical records; eligible patients treated after ethics approval will be enrolled prospectively using the same criteria.

説明

Inclusion Criteria:

  1. Age ≥18 year.
  2. Relapsed or refractory large B-cell lymphoma (LBCL) after one or more prior lines of systemic therapy, including diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS); diffuse large B-cell lymphoma transformed from follicular lymphoma (tFL); grade 3B follicular lymphoma (FL3B); primary mediastinal large B-cell lymphoma (PMBCL); and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit/triple-hit lymphoma, DHL/THL).
  3. Completion of CAR-T cell infusion at this center.
  4. Receipt of BTK inhibitor-containing bridging therapy after leukapheresis and before lymphodepleting chemotherapy.
  5. Documented, evaluable disease status after bridging therapy and before CAR-T cell infusion, based on imaging assessments or clinical records.
  6. Documented, evaluable disease status after bridging therapy and before CAR-T cell infusion, based on imaging assessments or clinical records.

Exclusion Criteria:

  1. Inability to verify the specific BTK inhibitor(s) used, treatment start and stop dates, or information on combination therapy, thereby precluding confirmation of exposure to BTK inhibitorcontaining bridging therapy.
  2. Absence of disease assessment data between bridging therapy and CAR-T cell infusion, with post-bridging disease status not determinable from imaging reports or medical records.
  3. Major discrepancies in key baseline or treatment data that persist after review of medical records, imaging, and treatment documentation, precluding determination of bridging exposure or group assignment.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:OTHER

コホートと介入

グループ/コホート
介入・治療
Bridging Response (CR/PR)

Participants with R/R LBCL who received BTK inhibitor-containing bridging therapy and underwent CAR-T cell infusion at this center. Based on the most recent routine disease assessment after bridging therapy and before CAR-T infusion, participants in this cohort achieved complete response (CR) or partial response (PR). Treatments were determined as part of usual clinical care and were not assigned by the study.

Bridging therapy containing a BTK inhibitor, including ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, pirtobrutinib, or another BTK inhibitor, administered after leukapheresis and before lymphodepleting chemotherapy as part of usual clinical care. Treatment selection, dose, duration, and combination therapy are determined by treating physicians and are not assigned or modified by the study.

CAR-T cell therapy administered after lymphodepleting chemotherapy as part of usual clinical care. CAR-T target(s), product, dose, and infusion schedule are determined by treating physicians and clinical practice, and are not assigned or modified by the study.

No Bridging Response (SD/PD)

Participants with R/R LBCL who received BTK inhibitor-containing bridging therapy and underwent CAR-T cell infusion at this center. Based on the most recent routine disease assessment after bridging therapy and before CAR-T infusion, participants in this cohort had stable disease (SD) or progressive disease (PD). Treatments were determined as part of usual clinical care and were not assigned by the study.

Bridging therapy containing a BTK inhibitor, including ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, pirtobrutinib, or another BTK inhibitor, administered after leukapheresis and before lymphodepleting chemotherapy as part of usual clinical care. Treatment selection, dose, duration, and combination therapy are determined by treating physicians and are not assigned or modified by the study.

CAR-T cell therapy administered after lymphodepleting chemotherapy as part of usual clinical care. CAR-T target(s), product, dose, and infusion schedule are determined by treating physicians and clinical practice, and are not assigned or modified by the study.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Best objective response rate after CAR-T cell infusion
時間枠:At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.

The proportion of participants who achieve complete response (CR) or partial response (PR) at any time after CAR-T infusion and before first progression, death, initiation of new anti-lymphoma therapy, or last evaluable disease assessment. Participants without CR/PR before these events are classified as nonresponders; progression or death after CR/PR does not change responder status.

At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.

二次結果の測定

結果測定
メジャーの説明
時間枠
Duration of response
時間枠:From first documented CR or PR to disease progression or death from any cause, whichever occurs first, assessed up to 10 years.

Among participants who achieve CR or PR, duration of response is measured from the date of first documented CR or PR to disease progression or death from any cause, whichever occurs first. Participants without progression or death will be censored at the last evaluable disease assessment or before initiation of subsequent anti-lymphoma therapy.

From first documented CR or PR to disease progression or death from any cause, whichever occurs first, assessed up to 10 years.
Complete response rate at 1 month after CAR-T cell infusion
時間枠:Approximately 1 month after CAR-T cell infusion.
Approximately 1 month after CAR-T cell infusion.
Best complete response rate after CAR-T cell infusion
時間枠:At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.
At approximately 1 and 3 months after CAR-T cell infusion and at subsequent scheduled follow-up visits through study completion.
Number of participants with CAR-T treatment-emergent adverse events
時間枠:From CAR-T cell infusion to last follow-up.

The number and percentage of participants with any adverse event occurring after CAR-T cell infusion will be reported. Safety events include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections, prolonged cytopenia, death, and other clinically documented adverse events considered related to CAR-T cell therapy. CRS and ICANS will be graded according to ASTCT consensus criteria; other events will be collected from routine clinical, laboratory, and medical-record data.

From CAR-T cell infusion to last follow-up.
Objective response rate at 1 month after CAR-T cell infusion
時間枠:Approximately 1 month after CAR-T cell infusion.
Approximately 1 month after CAR-T cell infusion.
Objective response rate at 3 month after CAR-T cell infusion
時間枠:Approximately 3 months after CAR-T cell infusion.
Approximately 3 months after CAR-T cell infusion.
Complete response rate at 3 months after CAR-T cell infusion
時間枠:3 months after CAR-T cell infusion
3 months after CAR-T cell infusion
Progression-free survival
時間枠:From CAR-T infusion to first progression, death, or last follow-up.
From CAR-T infusion to first progression, death, or last follow-up.
Overall survival
時間枠:From CAR-T infusion to death from any cause or last follow-up.
From CAR-T infusion to death from any cause or last follow-up.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2028年12月1日

研究の完了 (推定)

2029年12月1日

試験登録日

最初に提出

2026年11月2日

QC基準を満たした最初の提出物

2026年11月10日

最初の投稿 (実際)

2026年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する